Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured News from MarketBeat Media 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. That also means these companies report negative earnings (i.e., are not profitable) and have little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. Just like Microsoft and Adobe rode the software wave in Web 1.0, RAD Intel is riding the AI software wave in 2025. Their product helps brands instantly find the right audience and message using AI – solving the #1 waste in marketing: misfired ad spend.
Already trusted by a who's-who of Fortune 1000 brands and leading global agencies – with recurring seven-figure partnerships in place. With a Nasdaq ticker reserved, $RADI, it's early – but very real. $0.85 Won't Last – Secure Your Shares Now. Even if a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies typically receive the analyst coverage that attracts institutional investment. However, getting in on one of these medical stocks and having it hit is like winning the lottery. In an instant, investors could see 3x, 5x, or even 10x returns. Others may never pan out. That's why many investors interested in penny stocks distribute a lump sum across a number of biotech companies. If it is a numbers game, diversification can be an effective strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but offer the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for the early detection of cancer. Unlike many penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert–the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s digital health pioneers. With over 60,000 new colorectal cancer cases annually in Germany, the market opportunity is material. Mainz Biomed is also developing a non-invasive blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. That program, however, is still years away from potential commercial approval. The risks are substantial. ColoAlert is not yet available in the United States, and despite early European sales and plans to expand into South America, revenue remains minimal. That's why the company included “Going Concern” language in its Sept. 26 SEC filing and subsequently filed a $150 million mixed shelf offering. For now, that funding strategy helps keep the MYNZ share price above $1 and avoids a delisting notice. The company must start generating meaningful revenue to change its financial outlook. If it succeeds, even a relatively small investment could produce sizable returns; if it doesn't, the downside is significant. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech with a potentially disruptive approach to antiviral treatment, but it also carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new method for infectious disease treatment. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical data indicating strong antiviral activity. But like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to keep programs moving. Recent filings reported limited cash on hand, so investors should expect the possibility of future dilution. Still, if one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space. Both Mainz Biomed and NanoViricides illustrate the classic small-cap biotech tradeoff: high risk and high potential reward. Investors considering these names should do thorough due diligence, size positions appropriately, and be prepared for potential dilution and long timelines to commercialization.
| 
